NEW YORK (GenomeWeb News) – Life Technologies today announced that it has signed a research agreement and licensing deal with Harvard University focused on stem cell assays.

The firm said that it has acquired exclusive rights from Harvard to develop a panel of characterization assays designed to rapidly evaluate human pluripotent stem cells for their use in a variety of discovery and translational research applications. The panel is expected to be offered on Life Tech's Ion Torrent semiconductor sequencing platforms, as well as its PCR-based systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.